title: The tetrapeptide acetyl-serine-aspartyl-lysine-proline improves skin flap survival and accelerates wound healing.
abstract: The tetrapeptide acetyl-serine-aspartyl-lysine-proline (AcSDKP) has recently been recognized as a potent angiogenic factor. Given the importance of vascular blood supply in the process of tissue repair we have investigated the ability of AcSDKP to contribute to the repair of cutaneous injuries by using dorsal and abdominal skin flap models. Postoperative subdermal AcSDKP injections (5 microg/kg/injection twice a day for 3 days following flap elevation) prevented marginally perfused areas from undergoing necrosis. Mean skin survival area of abdominal and dorsal flaps ranged, respectively, from 50.9+/-19.3 and 53.4+/-4.2% in the control groups to 66.4+/-7.5 and 74.7+/-6.6% in AcSDKP-treated groups. Furthermore, in an ex vivo assay, AcSDKP applied locally to skin explants at doses from 10(-8) to 10(-5) M improved survival of the explanted skin exposed to UVB irradiation at 10 J/cm2. Increased reepithelialization, as well as higher levels of expression of basal keratin 14 and increased expression of fibronectin was observed after topical application of AcSDKP. These data provide experimental evidence that AcSDKP can improve the viability of ischemic skin flaps in the rat by promoting angiogenesis. Moreover, it enhances wound healing of injured avascular skin explants. Thus, these findings identify AcSDKP as a new tissue-repair agent and suggest its potential clinical use for the management of skin wounds.
authors.affiliation: Institut de Myologie, INSERM U582, Paris, France. y.fromes@myologie.chups.jussieu.fr
authors.forename: Yves
authors.initials: Y
authors.lastname: Fromes
authors.forename: Jian-Miao
authors.initials: JM
authors.lastname: Liu
authors.forename: Milica
authors.initials: M
authors.lastname: Kovacevic
authors.forename: Jérôme
authors.initials: J
authors.lastname: Bignon
authors.forename: Joanna
authors.initials: J
authors.lastname: Wdzieczak-Bakala
mesh_terms: D043925:Angiogenesis Inducing Agents / Q000494:pharmacology*; D000818:Animals; D005353:Fibronectins / Q000378:metabolism; D006085:Graft Survival / Q000187:drug effects*; D006801:Humans; D053547:Keratin-14 / Q000378:metabolism; D008297:Male; D009842:Oligopeptides / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D017208:Rats, Wistar; D012867:Skin / Q000378:metabolism / Q000473:pathology; D013524:Surgical Flaps / Q000098:blood supply / Q000473:pathology*; D046509:Tissue Culture Techniques; D014945:Wound Healing / Q000187:drug effects*
chemical_list: D043925:Angiogenesis Inducing Agents; D005353:Fibronectins; D053547:Keratin-14; D009842:Oligopeptides; C058504:goralatide